<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387825</url>
  </required_header>
  <id_info>
    <org_study_id>SCI-1505-15/15-1</org_study_id>
    <secondary_id>290250</secondary_id>
    <nct_id>NCT04387825</nct_id>
  </id_info>
  <brief_title>Safety Of Fat Micrografts With Adipose-Derived Stromal Vascular Fraction In Hands Of Patients With Systemic Sclerosis</brief_title>
  <official_title>Lipograft Safety Enriched With Vascular Stromal Fraction Derived From Adipose Tissue, to Treatment of Digital Joint Fibrosis and Refractory Ischemic Digital Ulcers Caused by Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Council of Science and Technology, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis (SS) causes microvascular alteration in the hand and subsequently pain,
      skin fibrosis, and osteoarticular deformities. These injuries initiate functional decline of
      the hand and decrease patient quality of life.

      Local application of adipose-derived stromal vascular fraction (ADSVF) has been proposed as
      an emerging treatment. There are reports about the good results obtained after ADSVF
      treatment in this kind of patients. For these reasons , we aimed to evaluate the safety and
      clinical effect of application of fat micrografts enriched with ADSVF to the hands of
      patients with SS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The regenerative properties of adipose stem cells (ASCs) existing in the mixed cell fraction
      obtained by enzymatic digestion of adipose tissue, termed adipose-derived stromal vascular
      fraction (ADSVF), were initially described in 2002. These cells have the characteristics of
      being multipotent and exerting local angiogenic, anti-inflammatory, antifibrotic,
      immunomodulatory, and regenerative effects after application. ASCs express their angiogenic
      properties most effectively in a hypoxic environment.

      For the above reasons, and because of its abundance in fat, easy acquisition, and almost
      immediate availability for use, ADSVF has positioned itself as an alternative for repair and
      regeneration of ischemic tissue.

      Application of decanted fat, centrifuged fat, and ADSVF, has consistently and significantly
      improved pain, Raynaund Phenomen, and healing of digital ulcers in the hands of patients with
      SS, and thus improved their quality of life. Other inconsistent benefits have also been
      reported, such as decreased digital circumference, improvement in digital mobility and
      strength, improvement in formation of new subungual capillaries, and improvement in function
      through evaluation of the Cochin scale.

      Based on the above findings, and because changes in the hands of patients with SS may arise
      through loss of adipocytes and defective stem cell function, we designed the present study
      with the aim of evaluating the safety, reproducibility, and clinical effects of application
      of fat micrografts enriched with ADSVF to the hands of patients affected with SS in a
      controlled clinical trial.

      The experimental and control groups each contained 10 patients diagnosed with SS according to
      the criteria of the American College of Rheumatology and the LeRoy-Medsger criteria.

      It was decided to carry out the treatment on the most affected hand of the patients, which
      was the right hand in the entire experimental group. ADSVF-enriched fat micrografts were
      applied to the experimental group. Evolution and medical therapy effects were observed in the
      control group.

      The fat was obtained by liposucction and the ADSVF was processed in laboratory.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2015</start_date>
  <completion_date type="Actual">May 2020</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Adipose Derived Stromal Vascular Fraction (ADSVF) was obtained in a laboratory by enzymatic digestion of fat graft harvested by liposuction. This ADSVF and micro fat grafts were applied into the hands with fibrosis and digital ulcers caused by Systemic Sclerosis in the experimental group. The control group was treated with medical treatment only</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain before the treatment and every day during one week after the treatment, and each 28 days after de first week until the 168 day</measure>
    <time_frame>168 days</time_frame>
    <description>Evaluation with Numerical Pain Rating Scale(NPRS) before, and after the intervention. The minimum value is 0 and maximum is 10. High value is worst</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Raynaud Phenomenon</measure>
    <time_frame>168 days</time_frame>
    <description>Frequency, number of events per day/week;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Raynaud Phenomenon</measure>
    <time_frame>168 days</time_frame>
    <description>Duration of minutes in every event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Digital Total active Motion</measure>
    <time_frame>168 days</time_frame>
    <description>Goniometry, kapandjy Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital oximetry</measure>
    <time_frame>168 days</time_frame>
    <description>Transcutaneous Oximetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital Ulcers</measure>
    <time_frame>168 days</time_frame>
    <description>Number of ulcers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status and disability index</measure>
    <time_frame>168 days</time_frame>
    <description>Evaluated by Sclerosis Health assessment Questionnarie (SHAQ) scale, before and at the end of the study. The value are from 0 to 3. A result &gt;1.25 is worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand Function</measure>
    <time_frame>168 days</time_frame>
    <description>Cochin Scale, the values are from 0 to 90, higher values means poor function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life, before de treatment and at the end of the study</measure>
    <time_frame>168 days</time_frame>
    <description>Short Form 36 (SF-36) scale. High values is poor patient health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascularity of the nail bed</measure>
    <time_frame>168 days</time_frame>
    <description>Videocapillaroscopy by field</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin affection of the hand</measure>
    <time_frame>168 days</time_frame>
    <description>Modified Rodnan scale, the values are from 0 to 51. High values higher skin fibrosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Evolution and medical therapy effects were observed in the control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADSVF application in the right hand</intervention_name>
    <description>40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Medical treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with SS, according to the criteria of the American College of
             Rheumatology and those of LeRoy-Medsger.

          -  Over 18 years old,

          -  BMI&gt; 18 kg / m2.

          -  Patients received stable vasoactive and immunosuppressive therapies, for at least 1
             month before being enrolled in the study, and this was continued unchanged throughout
             the study.

        Exclusion Criteria:

          -  infected digital ulcers

          -  comorbidities that could affect hand function

          -  alcoholism

          -  drug abuse

          -  history of family cancer

          -  Patients with hyperbaric therapy one month before

          -  Botulinum toxin one month before

          -  surgical sympathectomy one month before
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Hinojosa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion salvador Zubiran</name>
      <address>
        <city>Mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 10, 2020</study_first_submitted>
  <study_first_submitted_qc>May 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>Mart√≠n Iglesias</investigator_full_name>
    <investigator_title>Plastic Surgeon</investigator_title>
  </responsible_party>
  <keyword>Hand deformities in Systemic sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

